Anyone who took diabetes drugs Onglyza or Kombiglyze XR and suffered heart failure.
What's Going On?
Attorneys across the country are looking into lawsuits in light of concerns that Onglyza and Kombiglyze XR can increase patients' risk of heart failure.
Type of Lawsuit
Attorneys across the country are investigating lawsuits on behalf of people who took Onglyza or Kombiglyze XR after reports surfaced that the diabetes drugs carry an increased risk of heart failure.
How Lawsuits Can Help Cardiac Failure Patients
It has been alleged that the makers of Onglyza and Kombiglyze XR didn’t do enough to warn patients and doctors about the risk of cardiac failure. As a result, we believe the drug companies are legally responsible for providing patients who suffered heart failure with compensation for:
Pain and suffering
Funeral expenses, in the event of death
Is This a Class Action?
This is not a class action lawsuit. Attorneys are pursuing these cases on an individual basis. This means that anyone who suffered heart failure after taking one of these drugs must hire their own attorney and file their own individual lawsuit. There is no class action users can “join” at this point, but we can help put you in touch with an attorney for help. (You can learn more about why cases involving defective drugs usually aren’t suited for class action lawsuits here).
Onglyza, Kombiglyze Linked to Heart Failure
The investigation into lawsuits over Onglyza and Kombiglyze XR was prompted by a string of announcements from the FDA regarding the drugs’ safety.
In February 2014, the FDA announced that it had requested clinical trial data from the maker of saxagliptin, which is sold under the brand names Onglyza and Kombiglyze XR. This announcement stemmed from the agency’s review of a study published in the New England Journal of Medicine that found a 27% increased risk of hospitalization for heart failure in people taking the drug.
Then, in April 2015, the FDA convened a panel to look at the cardiovascular safety of the drug. While the panel decided that the heart risks associated with the drug did not warrant restrictions on prescribing, it did nearly unanimously vote that the drugs needed label changes to better reflect the drugs’ heart failure risk.
After this announcement was made, lawyers began looking into the possibility of lawsuits against the makers of the drug and whether the drug companies provided proper warnings prior to the request for a label update.